Guidance
Our guidance for 2025 is provided below. We expect to achieve full-year 2025 organic growth in line with the prior year (6%). Organic growth is expected to be more modest in the first two quarters due to challenging comparables in Health and Tax & Accounting. The adjusted operating profit margin is expected to see improvement in 2025 led by Health and Corporate Performance & ESG.
| Performance Indicators | 2025 Guidance | 2024 Actual |
| Adjusted operating profit margin* | 27.1% - 27.5% | 27.1% |
| Adjusted free cash flow** | €1,250-€1,300 million | €1,276 million |
| ROIC* | 18%-19% | 18.1% |
| Diluted adjusted EPS** | Mid-single-digit growth | 11% |
*Guidance for adjusted operating profit margin and ROIC is in reporting currency and assumes an average EUR/USD rate in 2025 of €/$ 1.04. ** Guidance for adjusted free cash flow and diluted adjusted EPS is in constant currencies (€/$ 1.08). Guidance reflects share repurchases of €1 billion in 2025.
For definitions of the above performance indicators, please consult the Glossary
